We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $931M
1-Year Est. Return 41.63%
This Fund
S&P 500
This Quarter Est. Return
-10.62%
1 Year Est. Return
+41.63%
3 Year Est. Return
+181.18%
5 Year Est. Return
+113.34%
10 Year Est. Return
+1,823.73%
AUM
$2.76B
AUM Growth
-$25.9M
Cap. Flow
+$49.6M
Cap. Flow %
1.8%
Top 10 Hldgs %
58.38%
Holding
114
New
31
Increased
18
Reduced
24
Closed
20

Top Buys

Rank Stock Value
1
C icon
Citigroup
C
+$14.9M
2
DG icon
Dollar General
DG
+$14.5M
3
MJN
Mead Johnson Nutrition Company
MJN
+$12.2M
4
APTV icon
Aptiv
APTV
+$9.58M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$9.21M

Top Sells

Rank Stock Value
1
ACOR
Acorda Therapeutics
ACOR
+$11.8M
2
GS icon
Goldman Sachs
GS
+$8.41M
3
CCI icon
Crown Castle
CCI
+$7.34M
4
XOMA
Xoma
XOMA
+$7.26M
5
FURX
FURIEX PHARMACEUTICALS INC COM STK (DE)
FURX
+$5.55M

Sector Composition

Rank Sector Weight
1 Miscellaneous 52.76%
2 Consumer Discretionary 22.6%
3 Healthcare 22.19%
4 Consumer Staples 1.28%
5 Financials 0.7%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ONIT
26
CALL
Onity Group
ONIT
$284M
$21.5M 0.78%
36,667
+20,000
+120% +$13M
PCYC
27
DELISTED
PHARMACYCLICS INC
PCYC
$21M 0.76%
210,000
+45,000
+27% +$5.85M
GS icon
28
CALL
Goldman Sachs
GS
$279B
$20.5M 0.74%
125,000
+50,000
+67% +$8.41M
IMGN
29
DELISTED
Immunogen Inc
IMGN
$19.4M 0.7%
1,300,000
-350,000
-21% -$5.52M
INTC icon
30
CALL
Intel
INTC
$518B
$19.4M 0.7%
750,000
-250,000
-25% -$6.24M
AMGN icon
31
Amgen
AMGN
$204B
$18.5M 0.67%
150,000
– –
ITB icon
32
CALL
iShares US Home Construction ETF
ITB
$2.13B
$18.2M 0.66%
750,000
– –
NVDA icon
33
CALL
NVIDIA
NVDA
$5.12T
$17.9M 0.65%
+40,000,000
New +$17.1M
GILD icon
34
CALL
Gilead Sciences
GILD
$181B
$17.7M 0.64%
+250,000
New +$19.6M
HIG icon
35
CALL
Hartford Financial Services
HIG
$36.8B
$17.6M 0.64%
500,000
-650,000
-57% -$22.6M
BAC icon
36
CALL
Bank of America
BAC
$412B
$17.2M 0.62%
1,000,000
-750,000
-43% -$12.6M
APTV icon
37
CALL
Aptiv
APTV
$9.13B
$17M 0.61%
+250,000
New +$16M
CL icon
38
CALL
Colgate-Palmolive
CL
$69.3B
$16.2M 0.59%
250,000
– –
NKTR icon
39
Nektar Therapeutics
NKTR
$2.25B
$15.8M 0.57%
86,667
-20,000
-19% -$3.96M
JPM icon
40
CALL
JPMorgan Chase
JPM
$915B
$15.2M 0.55%
+250,000
New +$14.4M
C icon
41
Citigroup
C
$226B
$14.3M 0.52%
+300,000
New +$14.9M
ARRY
42
DELISTED
Array Biopharma Inc
ARRY
$14.1M 0.51%
3,000,000
– –
DG icon
43
Dollar General
DG
$27.7B
$13.9M 0.5%
+250,000
New +$14.5M
ALNY icon
44
Alnylam Pharmaceuticals
ALNY
$32.6B
$13.8M 0.5%
205,000
+80,000
+64% +$6.19M
BMRN icon
45
CALL
BioMarin Pharmaceuticals
BMRN
$12.5B
$13.6M 0.49%
200,000
-300,000
-60% -$22.1M
ACOR
46
DELISTED
Acorda Therapeutics
ACOR
$13.3M 0.48%
2,917
-2,916
-50% -$11.8M
OIH icon
47
CALL
VanEck Oil Services ETF
OIH
$2.01B
$12.6M 0.46%
+12,500
New +$11.9M
MJN
48
DELISTED
Mead Johnson Nutrition Company
MJN
$12.5M 0.45%
+150,000
New +$12.2M
AMGN icon
49
CALL
Amgen
AMGN
$204B
$12.3M 0.45%
100,000
– –
GM icon
50
General Motors
GM
$74.6B
$12M 0.44%
350,000
+100,000
+40% +$3.67M
1
2
3 4 5

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $931M AUM 47.97% 1-Year Est. Return
ACM
Ashe Capital Management Englewood Cliffs, New Jersey $931M AUM 4.95% 1-Year Est. Return
SAM
Sycomore Asset Management Paris, France $932M AUM 51.25% 1-Year Est. Return
NS
Night Squared New York $930M AUM 56.46% 1-Year Est. Return
PA
Planning Alternatives Birmingham, Michigan $933M AUM 28.32% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $933M AUM 56.2% 1-Year Est. Return
CICI
Capital Investment Counsel Inc Raleigh, North Carolina $929M AUM 53.07% 1-Year Est. Return
CAM
Claret Asset Management Montreal, Quebec, Canada $928M AUM 25.4% 1-Year Est. Return

Artal Group's Q1 2014 Portfolio in Review

As of Q1 2014, Artal Group held 114 positions worth $2.76B, down 0.93% from $2.79B the previous quarter. Its ten largest holdings account for 58% of the portfolio.

Artal Group's Q1 2014 filing shows 31 new, 18 increased, 24 reduced and 20 closed positions. Its largest new stake was Citigroup: 300,000 shares worth $14.3M. The largest sale was Acorda Therapeutics, an estimated $11.8M.

By sector, the portfolio is most concentrated in Miscellaneous at 53% of assets, up from 42% a quarter earlier, followed by Consumer Discretionary and Healthcare.

  • Artal Group's largest Q1 2014 buy was Citigroup: 300,000 shares worth $14.3M.
  • Artal Group added most to BioMarin Pharmaceuticals in Q1 2014, an estimated $9.21M increase.
  • Artal Group's biggest Q1 2014 reduction was Acorda Therapeutics, cutting an estimated $11.8M.
  • Artal Group fully exited Goldman Sachs in Q1 2014, selling an estimated $8.41M.
  • Artal Group's ten largest holdings make up 58% of its $2.76B portfolio in Q1 2014.
  • Artal Group opened 31 new positions and closed 20 in Q1 2014.
  • Artal Group's portfolio value fell 0.93% quarter-over-quarter to $2.76B.

Based on Artal Group's 13F filing for Q1 2014, filed 15 May 2014.